바이오테크 보도자료
-
- Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with chroni...
- 2023년 06월 25일
-
- IPS Strengthens Asia and Pacific Presence with New Managing Director, Matthew Shippey
- IPS, a leading provider of architecture, engineering, procurement, construction management, and validation services, announces the appointment of an industry-leading professional, Matthew Shippey, to support...
- 2023년 06월 25일
-
- At the double: leading vape technology brand FEELM shows off two latest advancements in Dubai
- FEELM - part of leading atomization technology company SMOORE - exhibited two game-changing innovations, which have been developed to ‘raise product performance’ across the disposable vape category, during a...
- 2023년 06월 23일
-
- Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
- Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medi...
- 2023년 06월 22일
-
- No Charge, 6000 Puffs: ‘Power Alpha’ Breaks the Glass Ceiling of Disposable Solution
- SMOORE, a global leader in atomization technology, displayed its groundbreaking disposable solution, ‘Power Alpha’, at the World Vape Show 2023 in Dubai (June 21st - 23rd). Just a few months ago, Power Alpha...
- 2023년 06월 22일
-
- Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)
- The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122 in amyotrophic lateral sclerosis (ALS). Th...
- 2023년 06월 22일
-
- Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase...
- 2023년 06월 21일
-
- Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
- Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously trea...
- 2023년 06월 18일
-
- SciMed (Asia), Life Science Sales and Service Distributing Subsidiary of PHC Holdings Corporation, Becomes Wholly Owned Subsidiary -- Acquisition Expands PHC Group’s Business Supporting Researchers and Healthcare Providers in Asia-Pacific --
- PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director and CEO: Shoji Miyazaki, hereafter PHCHD) announces that it has acquired the remaining 30% stake in its sub...
- 2023년 06월 16일
-
- Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
- Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) (HUTCHMED) today announced that the European Medicines Agency (EMA) has validated and accepted for regulatory review the ma...
- 2023년 06월 16일
-
- Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million
- Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million. This senior unsecured bond transaction is issue...
- 2023년 06월 16일
-
- First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies
- With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare has today announced the first patient scanned in a Phase I clinical trial[2] of a first-of-its kind fluor...
- 2023년 06월 15일
전시회
